Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
The following information was reported to gore: on april 27, 2022, three gore® viabahn® vbx balloon expandable endoprosthesis(s) (vbx device) were placed in the right and left iliac veins for treatment of deep vein thrombosis.On (b)(6) 2022.An additional vbx device was implanted in the iliac vein for treatment of an unknown etiology.On an unknown date the patient developed an infection, post operation and was placed on vancomycin and cefepime to treat the infection.On (b)(6) 2022, the patient underwent an angioplasty and thrombectomy to treat occluded devices.The patient did not experience any adverse consequences.
|